Pharmacokinetics of trapidil in patients with chronic liver disease.

J Clin Pharmacol

Department of Internal Medicine, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Germany.

Published: October 1996

The pharmacokinetics of trapidil were studied in 15 patients with chronic liver disease (12 with hepatic cirrhosis, 2 with alcoholic fatty liver, 1 with liver fibrosis). Trapidil was administered intravenously as a 100-mg bolus. Serum samples were analyzed for trapidil by means of high-performance liquid chromatography. Mean pharmacokinetic parameters were compared with those found in a previous study of 12 healthy volunteers. Total plasma clearance was decreased significantly in patients with hepatic cirrhosis (96 mL/ min versus 258 mL/min in healthy individuals and 252 mL/min in patients with noncirrhotic liver disease). No difference in clearance was observed between patients with compensated or decompensated cirrhosis, and portal hypertension did not affect this clearance of trapidil. It can be concluded that trapidil clearance is a parameter that is very sensitive to alterations in hepatic clearance caused by liver cirrhosis, and that the dosage of trapidil should be adjusted accordingly in such patients.

Download full-text PDF

Source
http://dx.doi.org/10.1002/j.1552-4604.1996.tb04756.xDOI Listing

Publication Analysis

Top Keywords

liver disease
12
pharmacokinetics trapidil
8
patients chronic
8
chronic liver
8
hepatic cirrhosis
8
patients
6
liver
6
trapidil
6
clearance
5
trapidil patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!